Meralys 0,5 Mg/Ml (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride is a selective alpha‑adrenergic agonist. When applied to the nasal mucosa, it stimulates alpha‑1 receptors on the blood vessels, causing vasoconstriction. This reduces blood flow and edema in the nasal lining, leading to decreased congestion and easier breathing.

The specific dosing regimen for Meralys 0,5 Mg/Ml is determined by the prescribing healthcare professional based on the patient’s age, condition, and response to therapy. Typical instructions involve a few sprays per nostril, not exceeding the recommended maximum duration of use.

Safety data for Xylometazoline Hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and always under the guidance of a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both Meralys (Xylometazoline) and oxymetazoline belong to the same class of topical alpha‑adrenergic agonists and share a similar mechanism of action. Xylometazoline may have a slightly longer duration of effect, but individual response varies, and choice often depends on local availability, physician preference, and patient tolerance.

Store Meralys 0,5 Mg/Ml at ambient temperature, preferably below 25 °C. Keep the bottle tightly closed in its original packaging, protect it from moisture and direct sunlight, and avoid freezing. Do not use the product if the solution appears discolored or contains particles.

Meralys is administered as a nasal spray. The user tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The same procedure is repeated in the other nostril if directed by the prescriber.

The most serious risks include rebound nasal congestion after prolonged use, significant increases in blood pressure, and rare cardiovascular events such as arrhythmias. If any severe symptoms such as persistent hypertension, chest pain, or worsening nasal blockage occur, discontinue use and seek medical attention promptly.

Meralys should be avoided in individuals with known hypersensitivity to Xylometazoline or any component of the formulation, in patients with severe hypertension or coronary artery disease unless advised by a physician, and in children younger than six years unless specifically prescribed.